Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
Bruton's tyrosine kinase (BTK) inhibitors in clinical trials
Jan A. Burger
Leukemia
Research output
:
Contribution to journal
›
Review article
›
peer-review
95
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Bruton's tyrosine kinase (BTK) inhibitors in clinical trials'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Clinical Trial
100%
Ibrutinib
100%
Bruton Tyrosine Kinase Inhibitor
100%
B Cell
66%
Mantle Cell Lymphoma
50%
B-Cell Chronic Lymphocytic Leukemia
33%
Bruton Tyrosine Kinase
33%
Lymphocyte
16%
Cancer
16%
Lymphadenopathy
16%
Lymphocytosis
16%
Phosphotransferase
16%
Cell Surface
16%
Disease
16%
Waldenström's Macroglobulinemia
16%
Protein Tyrosine Kinase
16%
Immune Deficiency
16%
B Lymphocyte Receptor
16%
Percutaneous Coronary Intervention
16%
Homing Receptor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Ibrutinib
100%
Bruton Tyrosine Kinase Inhibitor
100%
Mantle Cell Lymphoma
50%
Chronic Lymphatic Leukemia
33%
Bruton Tyrosine Kinase
33%
Protein Tyrosine Kinase
16%
Phosphotransferase
16%
Remission
16%
Immune Deficiency
16%
Lymphadenopathy
16%
Lymphocytosis
16%
B Lymphocyte Receptor
16%
Waldenstroem macroglobulinemia
16%
Homing Receptor
16%
Keyphrases
CC-292
20%
AVL-292
20%
Imbruvica
20%